These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 23925000)

  • 1. Development of replication-competent viral vectors for HIV vaccine delivery.
    Parks CL; Picker LJ; King CR
    Curr Opin HIV AIDS; 2013 Sep; 8(5):402-11. PubMed ID: 23925000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection.
    Liu Q; Li Y; Luo Z; Yang G; Liu Y; Liu Y; Sun M; Dai J; Li Q; Qin C; Shao Y
    AIDS; 2015 Mar; 29(6):649-58. PubMed ID: 25849828
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Live attenuated rubella vectors expressing SIV and HIV vaccine antigens replicate and elicit durable immune responses in rhesus macaques.
    Virnik K; Hockenbury M; Ni Y; Beren J; Pavlakis GN; Felber BK; Berkower I
    Retrovirology; 2013 Sep; 10():99. PubMed ID: 24041113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-replicating viral vector-based AIDS vaccines: interplay between viral vectors and the immune system.
    Sauter SL; Rahman A; Muralidhar G
    Curr HIV Res; 2005 Apr; 3(2):157-81. PubMed ID: 15853721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.
    Clarke DK; Hendry RM; Singh V; Rose JK; Seligman SJ; Klug B; Kochhar S; Mac LM; Carbery B; Chen RT;
    Vaccine; 2016 Dec; 34(51):6597-6609. PubMed ID: 27395563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurovirulence and immunogenicity of attenuated recombinant vesicular stomatitis viruses in nonhuman primates.
    Clarke DK; Nasar F; Chong S; Johnson JE; Coleman JW; Lee M; Witko SE; Kotash CS; Abdullah R; Megati S; Luckay A; Nowak B; Lackner A; Price RE; Little P; Kalyan N; Randolf V; Javadian A; Zamb TJ; Parks CL; Egan MA; Eldridge J; Hendry M; Udem SA
    J Virol; 2014 Jun; 88(12):6690-701. PubMed ID: 24696472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
    Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
    AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Sendai virus vector-based AIDS vaccine inducing T cell responses.
    Seki S; Matano T
    Expert Rev Vaccines; 2016; 15(1):119-27. PubMed ID: 26512881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral vectors as potential HIV-1 vaccines.
    Schnell MJ
    FEMS Microbiol Lett; 2001 Jun; 200(2):123-9. PubMed ID: 11425463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
    Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
    Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral immunization with a live coxsackievirus/HIV recombinant induces gag p24-specific T cell responses.
    Gu R; Shampang A; Nashar T; Patil M; Fuller DH; Ramsingh AI
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV).
    Shen YJ; Shephard E; Douglass N; Johnston N; Adams C; Williamson C; Williamson AL
    Virol J; 2011 May; 8():265. PubMed ID: 21624130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced expression of HIV and SIV vaccine antigens in the structural gene region of live attenuated rubella viral vectors and their incorporation into virions.
    Virnik K; Ni Y; Berkower I
    Vaccine; 2013 Apr; 31(17):2119-25. PubMed ID: 23474312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenoviruses as vectors for HIV vaccines.
    Gómez-Román VR; Robert-Guroff M
    AIDS Rev; 2003; 5(3):178-85. PubMed ID: 14598567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers.
    Virnik K; Ni Y; Berkower I
    Vaccine; 2012 Aug; 30(37):5453-8. PubMed ID: 22776214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HIV vaccine pipeline, from preclinical to phase III.
    Schultz AM; Bradac JA
    AIDS; 2001; 15 Suppl 5():S147-58. PubMed ID: 11816163
    [No Abstract]   [Full Text] [Related]  

  • 18. Development of an AIDS vaccine using Sendai virus vectors.
    Ishii H; Matano T
    Vaccine; 2015 Nov; 33(45):6061-5. PubMed ID: 26232346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. UV-inactivated vaccinia virus (VV) in a multi-envelope DNA-VV-protein (DVP) HIV-1 vaccine protects macaques from lethal challenge with heterologous SHIV.
    Jones BG; Sealy RE; Zhan X; Freiden PJ; Surman SL; Blanchard JL; Hurwitz JL
    Vaccine; 2012 May; 30(21):3188-95. PubMed ID: 22425790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using SHIVs to develop an anti-HIV-1 live-attenuated vaccine.
    Kuwata T; Miura T; Hayami M
    Trends Microbiol; 2001 Oct; 9(10):475-80. PubMed ID: 11597447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.